Adverum Biotechnologies, Inc.

DB:AVU0 Stock Report

Market Cap: €149.6m

Adverum Biotechnologies Valuation

Is AVU0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AVU0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AVU0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AVU0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVU0?

Key metric: As AVU0 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for AVU0. This is calculated by dividing AVU0's market cap by their current book value.
What is AVU0's PB Ratio?
PB Ratio1x
BookUS$144.12m
Market CapUS$157.27m

Price to Book Ratio vs Peers

How does AVU0's PB Ratio compare to its peers?

The above table shows the PB ratio for AVU0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average14.7x
HPHA Heidelberg Pharma
3x-33.0%€109.1m
VSC 4SC
53xn/a€58.5m
MDG1 Medigene
1.3x-4.1%€24.9m
FYB Formycon
1.4x30.8%€826.3m
AVU0 Adverum Biotechnologies
1x-16.9%€157.3m

Price-To-Book vs Peers: AVU0 is good value based on its Price-To-Book Ratio (1x) compared to the peer average (14.7x).

Price to Book Ratio vs Industry

How does AVU0's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
AVU0 1.0xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: AVU0 is good value based on its Price-To-Book Ratio (1x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is AVU0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVU0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AVU0's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AVU0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€7.05
€27.89
+295.6%
36.1%€37.54€9.39n/a7
Nov ’25€6.60
€27.06
+310.0%
34.0%€36.08€10.83n/a7
Oct ’25€6.20
€27.06
+336.5%
34.0%€36.08€10.83n/a7
Sep ’25€6.10
€27.06
+343.7%
34.0%€36.08€10.83n/a7
Aug ’25€6.75
€30.81
+356.5%
40.7%€55.07€13.77n/a7
Jul ’25n/a
€31.59
0%
38.4%€55.99€18.66n/a7
Jun ’25n/a
€32.65
0%
38.2%€55.45€18.48n/a6
May ’25n/a
€33.10
0%
38.2%€56.21€18.74n/a6
Apr ’25n/a
€36.82
0%
31.6%€55.22€18.41n/a5
Mar ’25€17.90
€39.05
+118.2%
23.3%€55.79€27.89n/a5
Feb ’25€9.55
€35.96
+276.5%
34.9%€56.78€18.93n/a5
Jan ’25€6.65
€35.96
+440.7%
34.9%€56.78€18.93n/a5
Dec ’24€7.25
€35.96
+396.0%
34.9%€56.78€18.93n/a5
Nov ’24€8.30
€35.96
+333.2%
34.9%€56.78€18.93€6.605
Oct ’24€14.10
€38.82
+175.3%
25.6%€54.81€27.41€6.204
Sep ’24€15.70
€38.82
+147.3%
25.6%€54.81€27.41€6.104
Aug ’24€19.40
€38.54
+98.7%
28.8%€53.36€26.68€6.753
Jul ’24€14.30
€37.02
+158.9%
35.4%€55.54€27.77n/a3
Jun ’24€11.20
€37.02
+230.6%
35.4%€55.54€27.77n/a3
May ’24€7.25
€30.80
+324.8%
50.4%€56.86€18.95n/a4
Apr ’24€6.48
€30.80
+375.0%
50.4%€56.86€18.95n/a4
Mar ’24€6.66
€35.40
+431.7%
46.4%€57.92€19.31€17.903
Feb ’24€5.86
€35.40
+504.1%
46.4%€57.92€19.31€9.553
Jan ’24€5.42
€35.40
+553.1%
46.4%€57.92€19.31€6.653
Dec ’23€6.31
€35.40
+460.6%
46.4%€57.92€19.31€7.253
Nov ’23€8.91
€44.26
+396.6%
32.7%€59.01€24.59€8.303

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Pharming Group

€498.9m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

7D

-1.0%

1Y

-32.7%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.46

7D

-3.4%

1Y

2.1%

Merck

US$249.2b

Operates as a healthcare company worldwide.

6MK

US$93.10

7D

-1.0%

1Y

-0.1%